--- title: "mRNA Personalized Cancer Vaccine! What Does Moderna's Breakthrough Mean?" type: "News" locale: "en" url: "https://longbridge.com/en/news/296415935.md" description: "The personalized mRNA cancer vaccine jointly developed by Moderna and Merck has succeeded in Phase III clinical trials, significantly reducing the risk of recurrence in high-risk melanoma patients. Boosted by this positive news, Moderna's stock price surged approximately 177%, while Merck rose nearly 13%. The two companies plan to communicate with regulators regarding marketing approval, with the product potentially approved as early as 2027. Wall Street investment banks view this as key to Moderna launching its oncology business, but opinions diverge on its commercial prospects" datetime: "2026-08-20T00:46:46.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296415935.md) - [en](https://longbridge.com/en/news/296415935.md) - [zh-HK](https://longbridge.com/zh-HK/news/296415935.md) generator: "portal-rs" --- # mRNA Personalized Cancer Vaccine! What Does Moderna's Breakthrough Mean? The personalized mRNA cancer vaccine jointly developed by Moderna and Merck has succeeded in a large-scale Phase III clinical trial, marking a milestone breakthrough in the field of tumor immunotherapy and validating the huge commercial potential of mRNA technology beyond respiratory diseases. As noted in an article by Wallstreetcn, the latest trial results show that the vaccine, intismeran autogene, combined with Merck's immune drug Keytruda, significantly reduced the risk of post-operative recurrence and distant organ metastasis in high-risk melanoma patients. Buoyed by this major positive news, **Moderna's stock price surged approximately 177% at the US market close**, possibly triggering a severe short squeeze during the session, while Merck also closed up nearly 13%, leading gains among Dow Jones Industrial Average components. Moderna CEO Stéphane Bancel called the results an "extraordinary milestone for mRNA science." The two companies plan to immediately engage with regulators regarding marketing approval applications, **with the product potentially gaining approval as early as 2027, and detailed data to be presented at upcoming international medical conferences.** According to Zhuifeng Trading Desk, Wall Street investment banks such as Goldman Sachs, JPMorgan, and Citigroup generally stated in their research reports on August 19 that **these data are the key to unlocking Moderna's oncology pipeline.** However, institutions hold significant divergence regarding the commercial prospects of the technology and the company's valuation, **with market focus shifting to the forthcoming detailed efficacy data and its application potential in other cancer types.** Elon Musk commented on social media that mRNA technology still holds immense potential in curing diseases. **Artificial RNA essentially turns disease cure into a software problem.** ## Clinical Endpoints Achieved, Unlocking Oncology Pipeline This Phase III clinical trial, named INTerpath-001, is the first study to demonstrate efficacy for a personalized cancer vaccine in the Phase III stage. The trial enrolled 1,137 high-risk melanoma patients who had undergone complete surgical resection. The results successfully met the primary endpoint of Recurrence-Free Survival (RFS) and the key secondary endpoint of Distant Metastasis-Free Survival (DMFS). Goldman Sachs believes this is **the first time Moderna has obtained positive pivotal clinical data outside its respiratory vaccine pipeline, marking the initial unlocking of its oncology vertical.** Based on this, Goldman Sachs raised the Probability of Success (PoS) for the vaccine in melanoma to 100% and significantly increased Moderna's 12-month target price from $67 to $120. JPMorgan also affirmed the clinical results. The bank pointed out that beyond the primary endpoint, **achieving the key secondary endpoint of DMFS holds extremely high clinical value.** Citing melanoma expert Yana Najjar, JPMorgan stated that the DMFS data is "extremely meaningful" and represents the true value proposition of the therapy. Furthermore, Georgina Long, the principal investigator of the trial, stated that this combination therapy has the potential to establish a new treatment paradigm in adjuvant melanoma therapy. ## Divergence on Commercialization Thresholds and Market Pricing Despite the technological breakthrough, Wall Street investment banks remain cautious about Moderna's valuation and commercial implementation. JPMorgan maintains its "Underweight" rating on Moderna, with a target price of $40. The bank believes that **the market had already priced in the success in melanoma (previously estimating an 85% success rate), and the sharp rebound in stock price was partly due to short covering.** Data shows that Moderna's previous short interest accounted for approximately 13.5% of its float. JPMorgan emphasized that while the vaccine, as a collaborative asset, is crucial for the company's return to profitability in a relatively small indication market, the current market capitalization already fully reflects this expectation. Citigroup maintains its "Neutral/High Risk" rating, with a target price of $60. Citigroup pointed out that although statistical significance brings positive visual effects, the Hazard Ratio (HR) for RFS, absolute separation, and specific event numbers have not yet been disclosed. > In the absence of these details, it is difficult to assess the magnitude of benefit, durability, and commercial relevance of the therapy in adjuvant melanoma treatment. Citigroup further emphasized that the commercialization threshold for personalized therapies is far higher than for off-the-shelf standardized drugs. The vaccine requires customized design based on the specific genetic mutation "fingerprint" of each patient's tumor, containing synthetic mRNA for up to 34 neoantigens. **This complex process involving tumor sequencing, manufacturing lead times, repeated dosing, and coordination with Keytruda will pose a severe test for future commercial promotion.** ## Cross-Cancer Validation Determines Ultimate Prospects The success of this Phase III melanoma trial is seen as a critical node in testing the feasibility of the mRNA personalized cancer vaccine technology path. As previously reported by Bloomberg, Jane Healy, Head of Early Oncology Development at Merck, stated that the medical community has pursued therapeutic cancer vaccines for over a century, with the potential advantage of extending patient survival without significantly increasing side effects. However, **whether this technology can be widely applied to other cancers is core to determining its ultimate market value.** Goldman Sachs remains optimistic, believing that the success in melanoma is indicative for other solid tumors. **Goldman Sachs raised the Probability of Success (PoS) for the vaccine in Non-Small Cell Lung Cancer (NSCLC) to 85% and expects its peak sales in global melanoma and NSCLC to reach $4.3 billion and $6.6 billion respectively (before deducting the 50/50 profit sharing with Merck).** **Citigroup and JPMorgan are relatively conservative.** Citigroup pointed out that melanoma is a highly immunogenic tumor **with established sensitivity to checkpoint inhibitors, so these results cannot be simply extrapolated to other cancer types such as lung, bladder, or kidney cancer.** Broad platform validation requires seeing equivalent efficacy in other tumor types and proving that personalized manufacturing can be reliably scaled up. Currently, the INTerpath series of projects between Moderna and Merck includes nine Phase II and Phase III clinical trials, covering multiple tumor types such as NSCLC, bladder cancer, and renal cell carcinoma. **The market is closely watching the forthcoming detailed data, as well as clinical results for other cancer types expected between 2026 and 2027, which will ultimately determine whether mRNA cancer vaccines can move comprehensively from a scientific "holy grail" to clinical reality.** ``` The above exciting content comes from Zhuifeng Trading Desk. For more detailed interpretations, including real-time analysis and frontline research, please join [**Zhuifeng Trading Desk ▪ Annual Membership**] Risk Warning and Disclaimer The market carries risks; invest with caution. This article does not constitute personal investment advice, nor does it consider the specific investment goals, financial status, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article align with their specific circumstances. Investment decisions made based on this content are the sole responsibility of the investor. ``` ### Related Stocks - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [MRK.US](https://longbridge.com/en/quote/MRK.US.md) - [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md) - [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md) - [GS.US](https://longbridge.com/en/quote/GS.US.md) - [JPM.US](https://longbridge.com/en/quote/JPM.US.md) - [C.US](https://longbridge.com/en/quote/C.US.md) - [.DJI.US](https://longbridge.com/en/quote/.DJI.US.md) - [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md) - [JPM-M.US](https://longbridge.com/en/quote/JPM-M.US.md) - [JPM-C.US](https://longbridge.com/en/quote/JPM-C.US.md) - [JPM-D.US](https://longbridge.com/en/quote/JPM-D.US.md) - [JPM-L.US](https://longbridge.com/en/quote/JPM-L.US.md) - [8634.JP](https://longbridge.com/en/quote/8634.JP.md) - [JPM-K.US](https://longbridge.com/en/quote/JPM-K.US.md) - [JPM-J.US](https://longbridge.com/en/quote/JPM-J.US.md) - [C-R.US](https://longbridge.com/en/quote/C-R.US.md) ## Related News & Research - [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md) - [Moderna’s 177% Surge Has Investors Asking What Comes Next](https://longbridge.com/en/news/296610623.md) - [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md) - [Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped](https://longbridge.com/en/news/296527593.md) - [Health care roundup: Market talk](https://longbridge.com/en/news/296381776.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**